Alexander A Daniels

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

J. Maris, Y. Mossé, M. Lemmon, 2023, Nature communications.

Serial profiling of circulating tumor DNA identifies dynamic evolution of clinically actionable genomic alterations in high-risk neuroblastoma.

Marilyn M. Li, J. Maris, Y. Mossé, 2022, Cancer discovery.